Redeye reiterates its positive stance following Physitrack’s Q1 results.
Redeye is optimistic about the new data from lymphoma patients treated with subcutaneous as well as ...
Enviable financials: 10% sales and 20% 10-year EPS CAGR Shunned by funds, but ESG and electrificatio...
Mixed markets; US strong but Germany weaker '24e-'26e EBIT down 4-3% on lowered Germany estimates Sh...
- Sales down 19% y-o-y in Q1 - Cost initiatives keep EBITA positive - Signs of a better market later...
- Stark nettoomsättning som uppgick till 3,5 MSEK (2,0) - Stärkt produkterbjudande och ökad funktion...
I det första kvartalet uppgick nettoomsättningen till 199,3 MSEK (106,6), en ökning med cirka 87,0 %...
Paper EBITDA PLN 109m, in line vs ABGSCe PLN 108m Group EBITDA miss driven by Rottneros Paper market...
Redeye comments on the start of a new phase I study of mitazalimab in local pancreatic cancer.
Active Biotech laddar för två akademiskt ledda studier inom sitt nya huvudområde, myelofibros.
CirChem har publicerat bolagets delårsrapport för det första kvartalet 2024 och visar på fortsatt st...
Redeye comments on the collaboration with University of Washington.
Under det första kvartalet år 2024 uppgick nettoomsättningen till 157,6 MSEK (148,4), motsvarande en...
Redeye has interviewed Freemelt’s regional presidents of the Americas and EMEA.
Redeye comments on Modelon's Q1 2024 report, which came in slightly weaker on both ARR and net reven...
Redeye gives its initial comments on the Q1 2024 report from Precise Biometrics, which came in above...
Redeye concludes that Q1 came in below its topline expectations, but in line on EBITDA-CAPEX (underl...
Redeye in this note briefly comments on Acconeer's Q1'24 report, which came in better than expected.
Redeye is encouraged by the strong gross margin in Q1 but at first glance, nothing in the report pro...
Q1 adj. EBIT of GBP 34m, above ABGSCe at GBP 20m Record high AUM, Valkyrie integrated Strong Q1, sto...
